RecruitingNCT06173947

SSM Predicts Outcomes of CLD Inpatients With Acute Liver Injury

Spleen Stiffness Measurement Predicts Short-term Outcomes of Chronic Liver Disease Inpatients With Acute Liver Injury: a Prospective, Observational and Multicentre Study


Sponsor

Nanfang Hospital, Southern Medical University

Enrollment

411 participants

Start Date

Jan 1, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

In this study, a single non-invasive tool, spleen stiffness measurement (SSM), was used to monitor the disease regression of inpatients with chronic liver disease (CLD) and acute liver injury. The present study aimed to establish an early diagnosis warning model for acute-on-chronic liver failure (ACLF) by SSM and investigate the effect of dynamic changes in SSM on the short-term prognosis (28-day, 90-day morbidity and mortality) of inpatients with CLD and acute liver injury.


Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This study is looking at whether a measurement called spleen stiffness (done through an ultrasound-like scan) can predict how severely ill patients with chronic liver disease will become when they have an episode of sudden liver injury (called acute-on-chronic liver failure). **You may be eligible if...** - You are between 18 and 80 years old - You have chronic liver disease (from any cause) - You are currently in the hospital with an acute liver injury, shown by a bilirubin level of 3 mg/dL or higher **You may NOT be eligible if...** - You have had liver transplant, a liver shunt procedure (TIPS), or spleen surgery before - You have advanced kidney failure, severe COPD, or had a heart attack within 3 months - You have been diagnosed with liver cancer or another active cancer - You are pregnant - Your jaundice (yellowing of the skin) is caused by a blocked bile duct Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEFibroScan® Expert 630

The SSM by FibroScan 630 was first performed after admission, repeated at the day 5±2 as soon as feasible, and finally evaluated before discharge.


Locations(1)

Hepatology Unit, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University

Guangzhou, Guangdong, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06173947


Related Trials